Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Insulin efsitora alfa
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Insulin efsitora alfa is a once-weekly basal insulin designed as a recombinant fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. This structure extends its half-life, enabling weekly subcutaneous dosing. It acts as an agonist at the insulin receptor, mimicking endogenous human insulin to regulate blood glucose levels. Developed by Eli Lilly, it is intended for the treatment of both type 1 and type 2 diabetes mellitus. Phase 3 clinical trials (QWINT program) have demonstrated non-inferior efficacy and safety compared to daily basal insulins such as degludec and glargine in reducing HbA1c in adults with diabetes[1][4][5][6][7].
- Brand names
- efsitora
- Other names
- Basal Insulin-FC
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on Insulin efsitora alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Insulin efsitora alfa.